📊 SOLV Key Takeaways
Is Solventum Corp (SOLV) a Good Investment?
Solventum demonstrates exceptional profitability metrics (26.2% operating margin, 30.8% ROE) but faces critical sustainability concerns with essentially flat revenue growth (+0.9% YoY) and negative free cash flow despite $369M operating cash flow. The dramatic net income improvement appears driven by cost management rather than organic growth, while high leverage (1.0x debt-to-equity) combined with weak liquidity (0.89x quick ratio) creates financial risk.
Why Buy Solventum Corp Stock? SOLV Key Strengths
- Exceptional operating margin of 26.2% and net margin of 18.7% demonstrates pricing power and operational efficiency
- Outstanding ROE of 30.8% shows highly effective capital utilization
- Strong profitability recovery with net income +224.8% YoY and EPS growth +221.7%
SOLV Stock Risks: Solventum Corp Investment Risks
- Revenue stagnation at +0.9% YoY raises serious concerns about market position and sustainable growth
- Negative free cash flow despite positive operating cash flow indicates structurally capital-intensive operations
- Quick ratio of 0.89x and current ratio of 1.23x suggest liquidity constraints; debt-to-equity of 1.0x is elevated for negative FCF company
- Dramatic earnings growth on flat revenue suggests one-time items or cost-cutting rather than organic business strength
Key Metrics to Watch
- Revenue growth trajectory - must accelerate significantly beyond current 0.9% to justify leverage
- Free cash flow generation - achieving positive FCF is critical for sustainability
- Debt reduction and leverage metrics - must improve given current negative FCF profile
Solventum Corp (SOLV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Solventum Corp presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
SOLV Profit Margin, ROE & Profitability Analysis
SOLV vs Healthcare Sector: How Solventum Corp Compares
How Solventum Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Solventum Corp Stock Overvalued? SOLV Valuation Analysis 2026
Based on fundamental analysis, Solventum Corp appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Solventum Corp Balance Sheet: SOLV Debt, Cash & Liquidity
SOLV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Solventum Corp's revenue has shown modest growth of 1% over the 5-year period. The most recent EPS of $7.79 reflects profitable operations.
SOLV Revenue Growth, EPS Growth & YoY Performance
SOLV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.1B | $122.0M | $0.70 |
| Q2 2025 | $2.1B | $89.0M | $0.51 |
| Q1 2025 | $2.0B | $137.0M | $0.78 |
| Q3 2024 | $2.1B | $122.0M | $0.70 |
| Q2 2024 | $2.1B | $89.0M | $0.51 |
| Q1 2024 | $2.0B | $237.0M | $1.37 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Solventum Corp Dividends, Buybacks & Capital Allocation
SOLV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Solventum Corp (CIK: 0001964738)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 30, 2026 | 4 | xslF345X06/wk-form4_1774914319.xml | View → |
| Mar 30, 2026 | 4 | xslF345X06/wk-form4_1774914270.xml | View → |
| Mar 30, 2026 | 4 | xslF345X06/wk-form4_1774914220.xml | View → |
| Mar 30, 2026 | 4 | xslF345X06/wk-form4_1774914106.xml | View → |
| Mar 30, 2026 | 4 | xslF345X06/wk-form4_1774914055.xml | View → |
❓ Frequently Asked Questions about SOLV
What is the AI rating for SOLV?
Solventum Corp (SOLV) has an AI rating of HOLD with 70% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SOLV's key strengths?
Claude: Exceptional operating margin of 26.2% and net margin of 18.7% demonstrates pricing power and operational efficiency. Outstanding ROE of 30.8% shows highly effective capital utilization.
What are the risks of investing in SOLV?
Claude: Revenue stagnation at +0.9% YoY raises serious concerns about market position and sustainable growth. Negative free cash flow despite positive operating cash flow indicates structurally capital-intensive operations.
What is SOLV's revenue and growth?
Solventum Corp reported revenue of $8.3B.
Does SOLV pay dividends?
Solventum Corp does not currently pay dividends.
Where can I find SOLV SEC filings?
Official SEC filings for Solventum Corp (CIK: 0001964738) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SOLV's EPS?
Solventum Corp has a diluted EPS of $8.88.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SOLV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Solventum Corp has a HOLD rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SOLV stock overvalued or undervalued?
Valuation metrics for SOLV: ROE of 30.8% (sector avg: 15%), net margin of 18.7% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy SOLV stock in 2026?
Our dual AI analysis gives Solventum Corp a combined HOLD rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is SOLV's free cash flow?
Solventum Corp's operating cash flow is $369.0M, with capital expenditures of $379.0M. FCF margin is -0.1%.
How does SOLV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 18.7% (avg: 12%), ROE 30.8% (avg: 15%), current ratio 1.23 (avg: 2).
Why is SOLV's return on equity (ROE) so high?
Solventum Corp has a return on equity of 30.8%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 18.7% net margin.